Pharming GroupXAMS:PHARM -0.82%80 EBITDA Margin % is 1.46% as of Mar. 2026, which is 88% below its 10-year median of 12.67. GuruFocus rates XAMS:PHARM with a GF Score™ of 80/100 and a GF Value™ of €1.26 (Fairly Valued). The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Pharming Group ranks better than 76.61% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharming Group's EBITDA for the
three
months ended in Mar. 2026 was €0.9 Mil. Pharming Group's Revenue for the
three
months ended in Mar. 2026 was €62.7 Mil. Therefore, Pharming Group's EBITDA margin for the quarter that ended in Mar. 2026 was 1.46%.
Pharming Group (XAMS:PHARM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pharming Group EBITDA Margin % Related Terms
Pharming Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pharming Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XAMS:PHARM vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Pharming Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pharming Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (XAMS:PHARM) has a EBITDA Margin % of 1.46% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharming Group and its competitors. This is 88% below median its historical median of 12.67. According to the industry distribution chart, Pharming Group ranks #221 out of 945 companies in the Biotechnology industry, placing it in the top 23.4%.
Is Pharming Group's EBITDA Margin % too high?
Pharming Group's current EBITDA Margin % of 1.46% is 88% below median its 10-year median of 12.67. Based on the distribution chart, Pharming Group ranks #221 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #221 out of 945 companies for EBITDA Margin %. This places Pharming Group in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharming Group and its competitors. Pharming Group's current EBITDA Margin % is 1.46%, which is 88% below median its own 10-year median of 12.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (XAMS:PHARM) is currently considered Fairly Valued. The stock's GF Value™ is €1.26, compared to a current price of €1.15 — trading 8.8% below its estimated fair value. The current EBITDA Margin % is 1.46%, which is 88% below median its 10-year median of 12.67. Pharming Group's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pharming Group (XAMS:PHARM), the current EBITDA Margin % is 1.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (XAMS:PHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of €1.15 is trading 8.8% below its estimated GF Value™ of €1.26.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for XAMS:PHARM:
EBITDA Margin %: 1.46% (88% below median its 10-year median of 12.67)
GF Value™: €1.26 vs. price of €1.15 (8.8% below fair value)
No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score
Get the complete analysis for XAMS:PHARM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAMS:PHARM has been successfully added to your 
